SEARCH

SEARCH BY CITATION

References

  • 1
    Pawlotsky J-M, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654659.
  • 2
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al., and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 3
    Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 4
    Definitions Working Group. Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Sponsored by National Institutes of Health and the Food and Drug Administration, Bethesda, MD, April 15–16, 1999.
  • 5
    Bonkovsky HL, Woolley M, and the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29: 264270.
  • 6
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Long-term histologic improvement and loss of detectable intra-hepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875881.
  • 7
    Lau D T-Y, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology 1998; 28: 11211127.
  • 8
    Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517524.
  • 9
    McHutchison JG, Davis GL, Esteban-Mur R, Poynard T, Ling M-H, Garaud J-J, Albrecht J, for The International Hepatitis Interventional Therapy Group. Durability of sustained virologic response in patients with chronic C after treatment with interferon α-2b alone or in combination with ribavirin [Abstract]. Hepatology 2001; 34: 244A.
  • 10
    Swain M, Heathcote EJ, Lai M-Y, Bain V, Feinman V, Sherman M, Kaita KD, et al. Long-lasting sustained virological response in chronic hepatitis C patients previously treated with 40 kD peginterferon alfa-2a (Pegasys) [Abstract]. Hepatology 2001; 34: 330A.
  • 11
    McHutchison JG, Poynard T, Esteban-Mur R, Davis GL, Goodman ZD, Harvey J, Ling M-H, et al., for the International Hepatitis Interventional Therapy Group. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002; 35: 688693
  • 12
    Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 11241130.
  • 13
    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al., for the IHIT Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174181.
  • 14
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al., for the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 14261432.
  • 15
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al., for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 14851492.
  • 16
    Zeuzem S, Feinman V, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 16661672.
  • 17
    Heathcote EJ, Shiffman ML, Cooksley WGE, Dusheiko GM, Lee SS, Balart L, Reindollar R, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 16731780.
  • 18
    Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 19
    McHutchison JG, Manns MP, Ling M-H, Koury K, Albrecht JK. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virologic response when ribavirin dose is expressed as mg/kg of body weight? [Abstract]. Hepatology 2001; 34: 329A.
  • 20
    Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30: 787779.
  • 21
    Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36 (Suppl 1): S145S151.
  • 22
    McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, et al., for the International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C infection. Gastroenterology (in press)
  • 23
    Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000; 32: 818823.
  • 24
    Foster GR. Interferons in host defense. Semin Liver Dis 1997; 17: 287295.
  • 25
    Lau JYN, Tam RC, Liang J, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 10021009.
  • 26
    Kasahara A, Hayashi N, Mochizuki K, Hiramatsu N, Sasaki Y, Kakumu S, Kiyosawa K, et al., and the Osaka Liver Disease Study Group. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. J Viral Hepat 2000; 7: 343351.
  • 27
    Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, Nakano S, et al., for the Yon-Ken HCV-HCC Follow-up Study Group. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J Viral Hepat 2000; 7: 414419.
  • 28
    Shindo M, Hamada K, Oda K, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001; 33: 12991302.
  • 29
    Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology 2001; 34: 595603.